Sandy Srinivas
Overview
Explore the profile of Sandy Srinivas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
8458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
2.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
3.
Rizkalla C, Srinivas S, Sangoi A
Int J Surg Pathol
. 2024 Sep;
:10668969241271957.
PMID: 39300817
Despite the College of American Pathologists' recommendation against diagnosing "fat invasion" in urinary bladder biopsies and transurethral resection of bladder tumor specimens (TURBT), some pathologists still consider this scenario as...
4.
Apolo A, Ballman K, Sonpavde G, Berg S, Kim W, Parikh R, et al.
N Engl J Med
. 2024 Sep;
392(1):45-55.
PMID: 39282902
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical...
5.
Del Rivero J, Else T, Hallanger-Johnson J, Kiseljak-Vassiliades K, Raj N, Reidy-Lagunes D, et al.
Oncologist
. 2024 Jul;
29(9):747-760.
PMID: 39037424
Importance: Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma. Observations: Mitotane is challenging...
6.
Rodriguez G, Parikh D, Kapphahn K, Gupta D, Fan A, Shah S, et al.
JAMA Oncol
. 2024 May;
10(7):949-953.
PMID: 38780960
Importance: Advance care planning (ACP) remains low among patients with advanced cancer. Multilevel interventions compared with clinician-level interventions may be more effective in improving ACP. Objective: To evaluate whether a...
7.
Bryce A, Crawford E, Agarwal N, Hussain M, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774467
Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are...
8.
Crawford E, Bryce A, Hussain M, Agarwal N, Beltran H, Cooperberg M, et al.
JU Open Plus
. 2024 May;
2(4).
PMID: 38774466
Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions...
9.
Song H, Leonio M, Ferri V, Duan H, Mari Aparici C, Davidzon G, et al.
Eur J Nucl Med Mol Imaging
. 2024 Apr;
51(9):2784-2793.
PMID: 38635050
Purpose: Lutetium-177 [Lu]Lu-PSMA-617 radioligand therapy (RLT) represents a significant advancement for metastatic castration-resistant prostate cancer (mCRPC), demonstrating improvements in radiographic progression free survival (rPFS) and overall survival (OS) with a...
10.
Schaeffer E, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):140-150.
PMID: 38626801
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic...